Chronic hepatitis B combined with non-alcoholic fatty liver disease
Conditions
Interventions
Experimental group:Weight loss and reversal of fatty liver disease can be achieved through diet, exercise and behavior management based on diet and exercise prescriptions developed by the attending ph
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18~60 years old, gender is not limited; 2. Meet the diagnostic criteria for CHB complicated with NAFLD as specified in this study; 3.BMI>=25Kg/m^2; 4. Voluntarily participate in this study and sign the informed consent form; 5. Have good compliance with the intervention and be able to complete the intervention and follow-up according to the requirements of the study.
Exclusion criteria
Exclusion criteria: 1. Previous history of liver cirrhosis, liver failure, ascites, gastrointestinal bleeding, varices, liver cancer-related surgeries, or ultrasound, CT, magnetic resonance and other imaging shows splenomegaly, portal vein widening, liver cancer or suspected malignant mass, etc.; 2. CHB patients who are taking special treatments such as interferon; 3. Liver hardness value greater than 20Kpa and/or platelets less than 150×10^9/L and/or gastroscopy indicates the presence of esophageal and gastric varices and other special conditions; 4. Patients who are using weight loss drugs or other ways to lose weight; 5. Combined with other serious systemic diseases, such as mental disorders, emphysema, heart failure, uremia, anemia, malignant tumors, etc.; 6. Any other diseases and conditions that can affect the patient's exercise safety and dietary intervention; 7. Pregnant or lactating women and other groups that are not suitable for enrollment; 8. Use of other fatty liver management programs or intervention studies; 9. Any other situation that the investigator thinks is unable to complete the study, such as unable to understand the study content, unable to record the uploaded data, mutilated limbs, and unable to cooperate with the completion of baseline screening and follow-up, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of weight loss within 12 weeks was >=5%; | — |
Secondary
| Measure | Time frame |
|---|---|
| Meet the indicators within 12W;HBV- DNA levels in patients taking anti-hepatitis B virus medications;The amount of medication required;Indicators of metabolic abnormalities in patients who did not use related drugs;Improvement in clinical symptoms;Fat controlled exhaustion parameters; | — |
Countries
China
Contacts
Public ContactLi Lufeng
The First Affiliated Hospital of Army Medical University
Outcome results
None listed